Midazolam

Pharmacological Class

  • Benzodiazepine (short-acting)
  • Sedative-hypnotic, anxiolytic, anticonvulsant

Mechanism of Action

  • Enhances GABA-A receptor activity by binding to benzodiazepine sites.
  • Increases frequency of chloride channel opening → hyperpolarization of neuronal membranes.
  • Produces sedation, anxiolysis, muscle relaxation, anticonvulsant, and amnestic effects.

Clinical Uses

  • Sedation: preoperative, procedural, and ICU sedation (often with opioids or propofol).
  • Induction of anesthesia: adjunct to general anesthesia.
  • Status epilepticus: alternative to lorazepam/diazepam.
  • Agitation in critically ill patients.
  • Palliative care: refractory agitation, dyspnea, seizures.

Dosage (Adults)

(always titrate to effect and adjust for age, weight, organ function)

  • Procedural sedation (IV):
    • 1–2 mg IV initially, then 0.5–1 mg q2–3 min PRN.
    • Usual total: 2–5 mg.
  • ICU continuous infusion (IV):
    • Loading: 0.01–0.05 mg/kg IV.
    • Infusion: 0.02–0.1 mg/kg/hr.
  • Status epilepticus (IV/IM):
    • 0.2 mg/kg IM/IV once (max 10 mg/dose).
  • Pediatrics: lower doses (0.05–0.1 mg/kg IV for sedation).

Pharmacokinetics

  • Onset: IV: 2–3 min; IM: 15 min; PO: 15–30 min.
  • Duration: Short (1–2 hr after single IV dose).
  • Metabolism: Hepatic via CYP3A4 → active metabolite (1-hydroxymidazolam).
  • Elimination: Renal excretion of metabolites.

Renal/Hepatic Considerations

  • Renal impairment: Active metabolite accumulates → prolonged sedation, especially in ICU.
  • Hepatic impairment: Decreased clearance, higher sensitivity.
  • Elderly/obese/critically ill: Prolonged half-life, lower dosing required.

Adverse Effects

  • CNS: Excessive sedation, respiratory depression, anterograde amnesia, delirium (esp. in ICU).
  • CV: Hypotension, bradycardia.
  • Respiratory: Dose-dependent respiratory depression, apnea (especially with opioids).
  • Others: Paradoxical reactions (agitation, aggression), tolerance with prolonged use.

Drug Interactions

  • CYP3A4 inhibitors (azoles, macrolides, protease inhibitors) → ↑ levels and prolonged sedation.
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin) → ↓ efficacy.
  • Additive CNS depression with opioids, alcohol, antihistamines, antipsychotics.

Monitoring

  • Vital signs: BP, HR, RR, SpO₂, level of consciousness.
  • Continuous ECG and respiratory monitoring during IV infusion or procedural sedation.
  • Accumulation with prolonged use in ICU – monitor for delirium and withdrawal.

Antidote

  • Flumazenil (benzodiazepine antagonist) for reversal in overdose or excessive sedation.
  • Use cautiously in chronic benzodiazepine users (risk of seizures).

Key Clinical Pearl:

Midazolam is very useful for short-term sedation and seizure management, but in the ICU prolonged infusion can lead to drug accumulation, delirium, and prolonged awakening. Alternatives like propofol or dexmedetomidine are often preferred for long-term sedation.